gold salts, and (13-9-21 ) months for D-penicillamine. The highest cumulative probability of drug survival at five years was for methotrexate (450/); that at 10 years was for gold salts (15%). Up to 600/o ofthe patients discontinued D-penicillamine in the first two years. Lack ofresponse was the major limiting factor for all drugs except D-penicillamine, for which it was toxicity. D-Penicillamine was associated with a greater rate of discontinuations because of toxicity in women and patients older than 65. Previous disease modifying antirheumatic drug administration did not influence current drug survival. Conclusion-Overall, gold salts remain useful for the treatment of rheumatoid arthritis over long periods of time in the population studied. Because of the high rate of continuation of treatment (survival) and the optimal efficacy and toxicity profiles observed with methotrexate after five years of treatment, it should be the drug of first choice for second line treatment of these RA patients.
(Ann Rheum Dis 1995; 54: 881-885) Rheumatoid arthritis (RA) is a chronic progressive disease that requires long term treatment. The major concern in management is to control disease activity.A" Current available data show that disease modifying antirheumatic drugs (DMARDs) are useful in short term studies," 1 but they are seldom continued for long periods, as a result of lack of efficacy, or toxicity. Clinical trials have been unable to show notable advantages of one DMARD over another,'2 therefore choice of a DMARD should be based on maximal efficacy with minimum toxicity. In this regard, most authors have stressed the need for long term comparative studies;'3'5 however, such studies under 'controlled' conditions are impractical because of high costs and logistic complexity. As an alternative, community based studies that analyse continuation on treatment with different DMARDs and use long follow ups and large numbers of patients are a common and useful approach to monitoring long term treatment of RA.1- '9 To assess the long term effectiveness of DMARDs in our population, we conducted an observational study of a large sample of Spanish RA patients followed for 12 years in a single rheumatology unit. We compared the survival (that is, continuation as treatment) of most DMARDs currently used in our community, and analysed the reasons for their discontinuation. To simplify terminology in this text, phrases such as 'drug survival' are used to imply 'cumulative probability of the patient continuing to take the drug'.
Patients and methods

PATIENTS AND DOSING SCHEDULES
In this open observational study, we reviewed the records of all RA Figure 1A represents the cumulative probability of survival for the four drugs, taking drug discontinuation as the end point. Drug survival for D-pencillamine was significantly lower than that of the other DMARDs when survival curves were compared by log rank test (p < 0-01). Median survivals indicated that more than 50% of the patients stopped taking D-penicillamine after only 18 months of treatment (table 2) . In contrast, 50% of patients taking methotrexate remained on the treatment after more than 50 months (table 2) . After 34 months of treatment, 50% of patients receiving gold salts or azathioprine were still taking the drug (fig lA) .
REASON FOR DMARD DISCONTINUATION
We recorded 573 discontinuations after a total of 991 starts of DMARD treatment. In most cases, gold salts, azathioprine and methotrexate were discontinued because of lack of response. Among patients receiving D-penicillamine, there were as many discontinuations because of toxicity as there were discontinuations because of lack of response (46% each) (table 3). No differences between the four drugs were found when survival curves were compared taking lack of response as the (fig 1 C) . Table 4 shows the toxicity profiles E 20 of the four DMARDs. Mucocutaneous abnormalities were the main reason for dis-,D-PN (2) continuation of gold salts and D-penicillamine. DMARDs in a large sample of Spanish RA patients. Conclusions regarding toxicity and efficacy should be drawn with caution because of various aspects of the study design. The decision to start or to stop treatment was guided by objective factors, but was based finally on the physician's clinical opinion, and thus a possible influence of the physician on the results cannot be excluded; other variables characteristic of retrospective study designs, may also have limited the ability of the study to assess the efficacy of drugs. Nevertheless, our findings may provide useful information on long term RA treatment because of the long term follow up, the large number of patients involved, and the clinical practice setting. Criteria for the assignment of cause for drug discontinuation have varied from report to report" and this should be borne in mind when the results of our survival analysis are compared with those of previous reports. Overall, our findings on drug survival, taking termination of treatment as the end point, presented no major differences compared with previous reports. Of interest, however, was the high median survivals of gold salts and azathioprine in our analysis. Depending on whether a study is based in a referral centre or in private practice, median survival for gold salts may vary from less than 14 months16 20-24 to 24 months. '8 19 In our study, within a public health care system, 50% of patients continued to take gold salts after 35 months and 38% after 60 months. Azathioprine survival was also 27 28 Our population was drawn from a South European ethnic group; whether this is associated with differences in drug survival remains to be proved. The study design and the nature of the system of health care provision may also account for variations in drug survival. Our data on gold salts survival suggest that the system of health care provision may influence drug survival. We did not analyse this particular issue, but it merits further evaluation in prospective studies.
Survival analysis using associated toxicity as the end point revealed D-penicillamine to have the poorest survival of all the DMARDs studied. The fact that most discontinuations occurred within the first two years of treatment, and 50% of them in the first 12 months, suggests that probability of discontinuation because of toxicity in patients receiving D-penicillamine should be expected within the first 18 to 24 months of treatment. This finding is in contrast with those for the other DMARDs studied, with which discontinuations because of side effects occurred gradually over their period of use. Age and gender may predispose to a greater incidence of adverse reactions to drugs,29 but we observed a consistent effect only in patients receiving D-penicillamine, among whom women, and patients older than 65, had a higher rate of drug discontinuation because of associated toxicity. Overall, we found a profile of associated toxicity leading to discontinuation that was in agreement with other reports. '8 19 30 31 Survival analysis with lack of response as an end point showed a similar survival on treatment for all the DMARDs studied, during the first four years of follow up; at five years, the worst survival was of D-penicillamine and the best, methotrexate. These findings should be interpreted with caution, as the assignment criteria may have constituted a source of bias. Drug discontinuations attributed to lack of response were in patients in whom there was absence of initial response, or loss of efficacy with time over the same period, but it is conceivable that on some occasions the drug was stopped in patients who presented both mild associated toxicity and a lesser measurable therapeutic effect. In those cases, designation of the reason for drug discontinuation may have been arbitrary. Nevertheless, our findings confirm previous reports indicating that discontinuations due to lack of response were fewer in patients treated with methotrexate after five years of treatment. 9 11 18 19 32-35 They also indicate that gold salts and azathioprine remain effective in long term use.
In summary, our long term follow up of DMARD treatment in Spanish RA patients showed that median survival on treatment exceeded 34 months for gold salts and azathioprine, and 50 months for methotrexate; that up to 60% of the patients discontinued D-penicillamine in the first two years of treatment, mainly because of toxicity; and that gender and age influenced drug survival only in patients treated with D-penicillamine, among whom women, and patients older than 65 years, presented a greater rate of discontinuations.
Because this was an open prospective observational study, conclusions regarding toxicity or efficacy of DMARDs should be interpreted with caution. Nevertheless, such studies represent one approach to the assessment of long term likelihood of drug continuation in clinical practice. In view of the differences we detected, the effects of factors such as genetic background, environment, or system of provision of medical care should be evaluated further. 
